A study of patients at the end of life in South Korea found high rates of exposure to broad-spectrum antibiotics, particularly among those with cancer, researchers reported today in Antimicrobial Stewardship & Healthcare Epidemiology.
Using data from the Korean National Health Insurance Database, researchers from Seoul National University analyzed antibiotic consumption during the final month, 6 months, and year of life in patients with and without cancer from 2006 to 2018.
Although smaller studies have found that antibiotic use during end-of-life (EOL) care is common, especially in cancer patients who are at risk for infection, the evidence supporting its use is limited. The study authors note that since cancer is the second-leading cause of death in most Organization for Economic Cooperation and Development countries, antibiotic use among terminal cancer patients is an important target for antimicrobial stewardship.
Increased use of broad-spectrum antibiotics
Of the more than 3.4 million decedents in the study population, 28.1% had cancer. Overall antibiotic consumption rates decreased slightly among decedents in their final month, with a less pronounced annual decrease rate among cancer decedents compared with non-cancer controls (0.4% vs 2.3%).
But over the study period, while narrow-spectrum antibiotics were used less, use and prescription of broad-spectrum antibiotics (beta-lactam/beta-lactamase inhibitor combinations, carbapenems, and polymyxins) steadily increased, and prescription rates were higher in cancer decedents than in non-cancer controls.
Specifically, carbapenem prescription rates increased from 5.6% to 18.5% (rate ratio [RR], 1.087; 95% confidence interval [CI], 1.085 to 1.088) in cancer decedents and from 2.9% to 13.2% (RR, 1.115; 95% CI, 1.113 to 1.116) in non-cancer decedents.
"Our findings suggest that patients at EOL, particularly those with cancer, are increasingly and heavily exposed to broad-spectrum antibiotics, which, although likely a consequence of increased AMR [antimicrobial resistance] over time, poses a great threat for further AMR emergence and spread," the study authors wrote. "There is a need to critically assess the tangible benefits of antibiotic use in EOL care and reconsider the perceptions of its noninvasive nature."